EMEA-002125-PIP01-17
Key facts
| Invented name |
Tagrisso
|
| Active substance |
Osimertinib (as mesilate)
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0222/2017
|
| PIP number |
EMEA-002125-PIP01-17
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Treatment of lung carcinoma (small cell and non-small cell carcinoma)
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
AstraZeneca AB (Sweden)
Tel. +46 855327591 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|